Company intelligence / Profile preview

Biodel Inc.

Danbury, Connecticut, United Statesbiodelag.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biodel developed ultra–rapid acting insulins and other diabetes therapies using proprietary formulation technologies. Its lead candidate Linjeta reached NDA review by the FDA but was not approved or commercialized. The company merged with another pharma entity in Boston in May 2016. Most clinical programs are discontinued or pending.

Therapeutic areas: Endocrinology
Modalities: Peptide drugs (notably insulin and glucagon formulations)Ultra rapid–acting insulin analoguesSublingual tablet formulations (VIAtab)Stabilized glucagon
Industry: Biotech

Drug pipeline

9 assets

VIAject

8 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed prior to merger.

Beyond the preview

Go deeper on Biodel Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biodel Inc..

Explore the full profile